新型嵌合病毒样颗粒疫苗对强毒新城疫病毒和传染性法氏囊病病毒攻击的保护效果
本研究基于新城疫病毒样颗粒载体平台和昆虫杆状病毒表达系统,开发了展示新城疫病毒HN蛋白和传染性法氏囊病病毒VP2蛋白的二价嵌合病毒样颗粒疫苗(ND-IBD cVLPs)。在无特定病原体鸡中,7日龄免疫50 µg纯化ND-IBD cVLPs、21日龄加强、42日龄攻毒,结果显示该疫苗诱导了针对NDV HN蛋白的高效血凝抑制抗体和针对IBDV VP2蛋白的酶联免疫吸附试验抗体,并对强毒NDV和IBDV攻击提供完全保护,减轻了NDV感染所致肺脏和IBDV感染所致法氏囊的病理损伤。
要点
- ND-IBD cVLPs基于ND VLPs载体平台和昆虫杆状病毒表达系统构建,展示NDV HN蛋白和IBDV VP2蛋白。
- 7日龄免疫50 µg、21日龄加强、42日龄攻毒,诱导针对NDV HN的血凝抑制抗体和针对IBDV VP2的酶联免疫吸附试验抗体。
- ND-IBD cVLPs对强毒NDV和IBDV攻击提供完全保护,并减轻肺脏和法氏囊病理损伤。
核心结论
- ND-IBD cVLPs有望成为安全高效的新型候选疫苗,用于有效预防新城疫和传染性法氏囊病,并拓展了ND VLPs外源蛋白递送平台的开发。
研究设计与样本
- 研究在无特定病原体鸡中评价ND-IBD cVLPs的免疫原性和保护效力。
- 鸡7日龄免疫50 µg纯化ND-IBD cVLPs,21日龄加强,42日龄攻毒。
主要发现
- ND-IBD cVLPs刺激产生针对NDV HN蛋白的高效血凝抑制抗体水平和针对IBDV VP2蛋白的酶联免疫吸附试验抗体水平。
- ND-IBD cVLPs对强毒NDV和IBDV攻击提供完全保护。
- ND-IBD cVLPs减轻NDV感染所致肺脏病理损伤和IBDV感染所致法氏囊病理损伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Newcastle disease (ND) and infectious bursal disease (IBD) pose significant threats to the chicken industry, causing substantial economic losses. Currently, immunization through vaccination is the most effective strategy to prevent ND and IBD but currently used traditional vaccines, including inactivated or attenuated vaccines, face challenges in achieving a balance between immunogenicity and safety. To develop a green and efficient novel vaccine for ND and IBD, we developed a bivalent chimeric virus-like particle vaccine (ND-IBD cVLPs) displaying the ND virus (NDV) HN protein and the IBD virus (IBDV) VP2 protein based on the ND VLPs carrier platform and insect baculovirus expression system. This study aimed to evaluate the immunogenicity and protective efficacy of ND-IBD cVLPs in specific pathogen-free chickens. Chickens were immunized with 50 µg of purified ND-IBD cVLPs at 7 days old, boosted at 21 days old, and challenged at 42 days old. The results demonstrated that ND-IBD cVLPs stimulated highly effective hemagglutination inhibition antibody levels against NDV HN protein and enzyme-linked immunosorbent assay antibody levels against the IBDV VP2 protein. Furthermore, ND-IBD cVLPs provided complete protection against virulent NDV and IBDV challenges and mitigated pathological damage to the lung caused by NDV infection and the bursa of Fabricius caused by IBDV infection. These findings suggest that ND-IBD cVLPs hold promise as a safe and efficient novel vaccine candidate for the effective prevention of ND and IBD, extending the development of a foreign protein delivery platform of ND VLPs.
引用
- Li J, Ding J, Chen K, et al. Protective effects of a novel chimeric virus-like particle vaccine against virulent NDV and IBDV challenge. Vaccine. 2023. PMID: 38065771. doi:10.1016/j.vaccine.2023.11.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。